Repligen

RGEN on Nasdaq. Repligen sells filters, pumps and chemicals that drugmakers use to make biologic medicines. Market value $10.7bn.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to September 2026. Quality checks use five annual reports, the latest for the year to December 2025.

Should I look at this?

Look carefully before going further

Read the warning sign in its own filings

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
past 12 months to September 2026
1.0%low

For every $100 of what the whole company costs, it produced $0.98 of spare cash in the past 12 months. A savings account pays about $4.

Price to profit
past 12 months to September 2026
587.5×full

You pay 587.5 years of operating profit for the business. The average large US company costs around 18.

Return on capital
five annual reports to December 2025
n/a

The filings do not give us enough to work this out.

Quality score: 80 of 100. Price score: 5 of 100. Our list needs 70 on quality and 60 on price.

$170.29 a share, 69% above its 1-year low

Over the past year the price has ranged from $100.99 to $198.87.

Pays no dividend

Price from Thursday’s close (19 November).

Five years of cash, in billions

0.1
0.1
0.1
0.1
0.1
0.1
2021202220232024202512 monthsto Sep '26
Revenue
$671m$802m$632m$634m$738m
Operating margin
24.9%28.0%7.5%-5.5%7.5%
Debt to equity
n/an/an/a0.270.26
Shares outstanding
0.06bn0.06bn0.06bn0.06bn0.06bn

Health checks

  • Free cash flow positive5 of 5 years
  • Accounting looks honest (Beneish)Nothing unusual
  • Financial strength (Piotroski)6 of 9
  • Profit backed by cash (accruals)Yes
  • Debt0.26× equity
  • Revenue growth, five yearsStrong, 15.1% a year
  • Buying back its own sharesNo, 15% more shares since 2021

The quarter to September 2026

How the business did, compared with the same quarter a year earlier.

  • Sales: $209 million last quarter, up 11% on a year ago.
  • A loss of $38 million, after a profit of $15 million a year ago.
  • It keeps 2 cents of each $1 of sales as operating profit, up from 0 cents a year earlier.
  • Spare cash over the past 12 months: $107 million, down from $110 million.
  • About the same number of shares as a year ago.
  • It has $171 million more cash than debt, down from $211 million a year ago.
Sales by quarter
Sales by quarter
Quarter toAmount
December 2024Not reported
March 2025$169m
June 2025$182m
September 2025$189m
December 2025$198m
March 2026$194m
June 2026$204m
September 2026$209m
Profit by quarter
Profit by quarter
Quarter toAmount
December 2024Not reported
March 2025$6m
June 2025$15m
September 2025$15m
December 2025$13m
March 2026$8m
June 2026$5m
September 2026-$38m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
n/a
Last annual report (10-K)
26 February 2026
Next quarterly (estimated, 10-Q)
29 January 2027

Who owns it

4 long-term investors we follow own it, unchanged from 4 last quarter. 480 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

3 investors own more than 5%.

  • FMR LLC
    Passive investor
    at least 13.0%+7.9 pts
    (filed with 1 related holder)
    Since 30 September 2026
  • BlackRock, Inc.
    Passive investor
    9.3%
    Since 31 March 2025
  • 5.0%
    Since 30 June 2026
  • Roy T. Eddleman Living Trust
    Passive investor
    Sold down below 5%
    Since 31 December 2024
  • Roy T. Eddleman Living Trust
    Passive investor
    Sold down below 5%
    Since 31 December 2025
  • Sold down below 5%
    Since 30 June 2026
  • The Vanguard Group
    Passive investor
    Sold down below 5%
    Since 13 March 2026

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

No insider bought shares on the open market in the last 12 months. 3 sold $8m, $8m of it under preset trading plans.

  • Loeillot Olivier
    Chief Executive Officer, Director
    Sold
    under a preset trading plan
    Date
    5 October 2026
    Shares
    5,535
    Price
    $187.29
    Value
    $1m
  • Loeillot Olivier
    Chief Executive Officer, Director
    Sold
    under a preset trading plan
    Date
    24 September 2026
    Shares
    12,946
    Price
    $190.00
    Value
    $2m
  • Loeillot Olivier
    Chief Executive Officer, Director
    Sold
    under a preset trading plan
    Date
    21 September 2026
    Shares
    5,426
    Price
    $180.00
    Value
    $976,680
  • Loeillot Olivier
    Chief Executive Officer, Director
    Sold
    under a preset trading plan
    Date
    4 September 2026
    Shares
    3,035
    Price
    $165.90
    Value
    $503,507
  • Loeillot Olivier
    Chief Executive Officer, Director
    Sold
    under a preset trading plan
    Date
    20 August 2026
    Shares
    5,426
    Price
    $180.00
    Value
    $976,680
  • Garland Jason K
    CFO
    Sold
    under a preset trading plan
    Date
    16 July 2026
    Shares
    530
    Price
    $150.00
    Value
    $79,500
  • Garland Jason K
    CFO
    Sold
    under a preset trading plan
    Date
    25 June 2026
    Shares
    733
    Price
    $145.00
    Value
    $106,285
  • Loeillot Olivier
    Chief Executive Officer, Director
    Sold
    under a preset trading plan
    Date
    21 April 2026
    Shares
    3,832
    Price
    $140.00
    Value
    $536,480
  • DAWES KAREN A
    Director
    Sold
    Date
    17 December 2025
    Shares
    275
    Price
    $161.00
    Value
    $44,275
  • Loeillot Olivier
    Chief Executive Officer, Director
    Sold
    under a preset trading plan
    Date
    25 November 2025
    Shares
    7,041
    Price
    $170.00
    Value
    $1m

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

1 serious warning sign in Repligen’s filings.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 26 Feb 2026, plus the 10-Q filed 30 Oct 2026 and 10 later 8-Ks.

  • Weak checks on its own accounts

    Serious

    The company said its checks on its own accounts did not work at the end of its latest quarter. Mistakes could slip into the numbers.

    “Based on such evaluation, the principal executive officer and principal financial officer have concluded that, as of the end of such period, the Company’s disclosure controls and procedures were not effective because of the previously reported material weaknesses in our internal control over financial reporting, which are described in Part II, Item 9A, “ Controls and Procedures ” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, which was filed with the Securities and Exchange Commission on February 26, 2026 (“Form 10-K”).”
    Show the full paragraph
    Under the supervision and with the participation of the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer, the Company carried out an evaluation as of September 30, 2026, of the effectiveness of the design and operation of the Company’s disclosure controls and procedures pursuant to Exchange Act Rules 13a-15(b) and 15d-15(b). Based on such evaluation, the principal executive officer and principal financial officer have concluded that, as of the end of such period, the Company’s disclosure controls and procedures were not effective because of the previously reported material weaknesses in our internal control over financial reporting, which are described in Part II, Item 9A, “ Controls and Procedures ” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, which was filed with the Securities and Exchange Commission on February 26, 2026 (“Form 10-K”). Notwithstanding the material weaknesses, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that the unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q are fairly stated in all material respects in accordance with generally accepted accounting principles in the United States for each of the periods presented.

    From the 10-Q filed 30 October 2026, Part I, Item 4. Controls and Procedures. Read it in the filing

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

  • It isn't cheap on profits: 587.5× operating profit.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from

The company just told the SEC about a big change. The deep dive shows what it means for the price you pay.

Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.